SEARCH FOR MARKERS OF EFFICIENCY OF BEVACIZUMAB IN METASTATIC COLORECTAL CANCER


Cite item

Full Text

Abstract

The inclusion of bevacizumab (Avastin) in the modern chemotherapy regimens has led to an increase of frequency of achieving objective response, median progression-free survival and overall survival, but at least 40 % of patients did not have the advantages of using this drug. Failure of treatment may be the result of a primary tumor resistance to treatment, as well as acquired resistance. The results of recent studies on search for markers of efficiency of bevacizumab (single nucleotide polymorphism of the VEGF gene, detection of recessive allele of CXCR1 interleukin-8 receptor, VEGFD expression, etc.) are discussed. The data obtained may contribute to a more rational approach to selecting the option of drug therapy.

References

  1. Gerger A, Zhang W, Yang D, et al. Angiogenesis gene polymorphisms and clinical outcome of metastatic colorectal cancer treated with first-line bevacizumab and oxaliplatin-based chemotherapy. Proc Am Soc Clin Oncol 2011 [abstr 3592].
  2. Hansen T, Christensen RD, Andersen RF, et al. The predictive value of single nucleotide polymorphisms in the vascular endothelial growth factor system in patients with metastatic colorectal cancer treated with bevacizumab plus chemotherapy as first-line treatment: Results of the phase III ACT trial NCT00598156 translational study. Proc Am Soc Clin Oncol 2011 [abstr 3600].
  3. Weickhardt J, Williams D, Lee C, et al. Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study. Proc Am Soc Clin Oncol 2011 [abstr 3531].
  4. Guchelaar H, Pander J, Bohringer S, et al. Genome-wide association study (GWAS) of the efficacy of capecitabine, oxaliplatin, and bevacizumab in metastatic colorectal cancer in the CAIRO2 trial of the Dutch Colorectal Cancer Group (DCCG). Proc Am Soc Clin Oncol 2011 [abstr 3609].
  5. George TJ, Liu H, Duckworth LV, et al. Determination of genomic profile to predict clinical response to FOLFOX plus bevacizumab in metastatic colorectal cancer. Proc Am Soc Clin Oncol 2011 [abstr 3598].

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies